 Shares of Gossamer Bio Inc. GOSS, 2.99 plunged 64.5 in premarket trading on Tuesday after Wall Street analysts questioned the performance of the companys experimental hypertension drug in a Phase 2 clinical trial. Though Gossamer said the drug, seralutinib, met the primary endpoint in a Phase 2 clinical trial, SVB Securities analyst Joseph Schwartz told investors that the therapy didnt outperform Merck Co. Inc.s MRK, -0.03 sotatercept. 